3 stocks I’m watching in October. Each of them has something that makes me worried a bit about. Also
2 extracted signals · 0 resolved · 2 still active
Smart X CapitalIndependent analyst profile- Source published
- 10 Oct 2026, 01:01 UTC
- Recorded by Tahlil Plus
- 10 Oct 2026, 02:03 UTC
AI-generated source summary
The analysis covers three stocks: Nvidia (NVDA), Resmed (RMD), and Copart (CPRT). Nvidia is highlighted for its dominance in the chip industry, particularly for AI, with strong revenue growth of $96 billion last quarter (more than double year-over-year) and a profit margin of 64.6%. The company has low debt and significant short-term assets. Despite a P/E ratio of 28.5, its business quality is considered hard to beat. A key risk identified is the heavy reliance on three customers, making up 44% of revenue, which could significantly impact Nvidia if any of them slow spending or develop their own chips. For Resmed, the market leader in sleep apnea machines, revenue grew 10% last year, with net income growing consistently for the past four years at an average of 18%. It boasts a strong balance sheet with ample cash and low debt. Its P/E ratio is 21.3, below its 5-year average of 30. The main concern is the potential decrease in demand for its machines due to the side effects of weight-loss drugs that help with sleep apnea. Copart, a market leader in auto auctions for salvaged vehicles, has seen its stock price drop 57.36% from its peak. Its P/E ratio is 18. While it has shown consistent year-over-year revenue growth for the last 20 years and has a strong balance sheet, its growth slowed last year due to an 8% decline in US insurance volumes and a major customer leaving. Its rival, IAA, experienced an 11% growth in auto volumes in the same period.
AI-generated summary based on the source content.
Signal outcomes at a glance
Tracking LiveSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
2 eligible signals linked to this case.
- Source processing completed
Source analysis and structured extraction completed.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- Live evaluation in progress
2 signals remain active.
Smart X Capital
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.